How long does Veozah actually take to work?

How long does it actually take for Veozah to start working?

Unlike drugs that ramp up over weeks, Veozah is prescribed at its full 45mg dose from day one — there's no titration schedule to climb through, which is part of why the onset window is relatively short and well documented. In the SKYLIGHT trials, researchers tracking daily hot flash diaries saw measurable improvement in both frequency and severity within the first week of treatment. That's not the full effect, though. The difference between fezolinetant and placebo reached statistical significance at week 4 — the point the FDA treats as the drug's established efficacy checkpoint — and kept building from there through week 12, which is where the fullest picture of the drug's effect in the trials shows up.

So the honest timeline has three stages: an early signal some women notice within days to a week, a clinically meaningful and statistically confirmed reduction by the one-month mark, and a fuller, more settled effect by around three months. None of that means nothing is happening for the first few weeks — it means the trial's own measuring points happen to land at four and twelve weeks, so that's where the most reliable data sits.

What does 'working' actually look like, week by week?

It helps to know what each stage of the trial data actually translates to in day-to-day terms, rather than picturing a light switch.

• Week 1: some women notice hot flashes feel slightly less intense or a bit less frequent — subtle enough that it's easy to write off as a good week, not a real trend yet.
• Week 4: this is where the drug's benefit becomes statistically distinguishable from placebo in trial data — in the SKYLIGHT 1 study, the 45mg group averaged roughly 2 fewer hot flashes a day than the placebo group at this point.
• Week 12: the effect had grown further by this mark — women on the 45mg dose averaged a bit over 2 fewer hot flashes a day than placebo, and about half of treated women had cut their hot flash frequency by 50% or more from where they started, versus roughly three in ten on placebo.
• Beyond week 12: in the trial's year-long extension, that level of relief held through 52 weeks for most women who stayed on treatment.

The trend matters more than any single day. A good night's sleep or a cool front rolling through can make day nine feel like a turning point that isn't real yet, and a rough week at month two doesn't necessarily mean the drug has stopped working.

It's been two weeks and I don't feel anything yet — is that normal?

Yes, and it's worth saying plainly rather than letting the trial's week-1 headline set unrealistic expectations. The 'improvement within a week' finding is a population-level average from a study of hundreds of women being tracked with structured daily diaries — it doesn't mean every individual woman feels a difference that fast. A meaningful number of trial participants didn't see their real shift until closer to the four-week mark, which is exactly why that's the point the data treats as the first confirmed checkpoint, not week one or two.

Perimenopausal hot flash patterns also fluctuate on their own regardless of medication — day-to-day hormone swings, stress, sleep, alcohol, and heat can all move the needle independently of whether the drug is doing its job. Two quiet weeks isn't proof of failure any more than two rough ones are proof it isn't working. Four weeks is the more meaningful checkpoint, and twelve is where the fullest picture in the trial data actually sits.

How do you actually know it's working, versus just a good week?

The SKYLIGHT trials didn't rely on participants' gut feeling — they used daily symptom diaries, logging the number and severity of hot flashes every single day and comparing the average across a stretch of time, not one day against another. That's a genuinely useful method to borrow. Tracking frequency and severity for two to four weeks and comparing that whole window to your pre-Veozah baseline gives you a real signal; comparing yesterday to today doesn't.

• Count, don't just recall — a quick daily tally (even a tally on your phone) beats trying to remember 'how this week felt' after the fact.
• Compare windows, not days — a rolling average across one to two weeks smooths out the noise that a single bad or good day introduces.
• Watch severity as well as frequency — some women notice the hot flashes keep happening but feel less intense or shorter before frequency drops, which is still a real early signal.

How long does Veozah stay in your system?

Fezolinetant's effective half-life is about 9.6 hours, and the drug reaches steady, stable blood levels after just two once-daily doses — roughly two days in. Because it clears the body on a similarly short timeline once you stop, there's no meaningful accumulation to worry about with daily use, and no long tail of the drug lingering in your system for weeks the way some medications do.

What happens if you miss a dose — does it reset the clock?

No. The official guidance is straightforward: if you miss your usual time, take the dose as soon as you remember, unless fewer than 12 hours remain before your next scheduled dose — in that case, skip the missed one and just take your next dose on the normal schedule. Never double up to make up for a missed pill.

One occasional missed dose doesn't undo weeks of building benefit, since the improvement reflects an ongoing biological effect rather than a single dose's worth of drug sitting in your system. That said, the same short half-life that clears the drug quickly also means blood levels dip relatively fast without a dose — so a pattern of frequently skipped or late doses, rather than one isolated miss, is what's more likely to show up as less steady symptom control.

Can anything slow down how fast or how well it works?

A few real variables are worth knowing about. Fezolinetant is broken down mainly by a liver enzyme called CYP1A2, which is exactly why the medications and habits that speed up or slow down that enzyme matter here. The current FDA label states that no clinically meaningful difference in fezolinetant exposure was seen in smokers — who have a moderately induced CYP1A2 system — during the registration trials. That said, a more recent clinical pharmacology study published in late 2024 found fezolinetant exposure in smokers running roughly half that of nonsmokers, attributing the gap to CYP1A2 induction from smoking. Those two findings sit somewhat in tension, and it's honest to say the newer data hasn't fully settled the question yet.

That's a completely different mechanism from the interaction that actually carries an FDA contraindication: strong CYP1A2 inhibitors like fluvoxamine block the same enzyme instead of revving it up, which pushes fezolinetant levels sharply higher rather than lower. The two effects point in opposite directions — one is about the drug possibly being cleared too fast, the other about it building up too high — and the fuller detail on that inhibitor interaction lives in the safety section of Veozah vs. HRT. Liver status matters too: Veozah is contraindicated in cirrhosis, and the required liver monitoring — baseline, then months 1 and 2, then months 3, 6, and 9 — exists to catch a problem early, not because slower response and liver risk are the same thing.

Does relief keep improving after week 12, or is that as good as it gets?

Based on the trial data, week 12 isn't a ceiling. A larger share of women met the trial's response threshold — at least a 50% drop in hot flash frequency — at week 12 than at week 4, suggesting the benefit was still building through that first quarter rather than plateauing early. In the year-long extension phase of the SKYLIGHT trials, that level of relief was generally sustained through 52 weeks for women who stayed on treatment.

Real-world experience adds a wrinkle the trial's own reporting doesn't fully capture: a recurring pattern among reviewers describes relief that felt strong in the early months gradually softening somewhere around the three-to-six-month mark, in some cases prompting them to stop. That's a documented pattern in patient reviews, not the drug's average trial course, and it isn't something to assume will happen to you — but it's worth knowing about going in. The fuller rundown of that pattern and what real users report is at what real Veozah reviews say.

How long should you give it before deciding it's not working for you?

There's no official cutoff written into the label spelling out when to call it quits, so this is a judgment call — but the trial's own structure offers a reasonable guide. Since the drug's benefit isn't fully established until around week 4, and kept building through week 12, giving it at least a full month before drawing conclusions, and ideally two to three months if the first few weeks feel underwhelming rather than clearly negative, matches how the drug actually behaves in the data. If you've hit the three-month mark with no real change in frequency or severity, that's a fair point to bring it up with your prescriber rather than assuming you just need to wait longer.

It's also worth remembering Veozah isn't the only non-hormonal or hormonal option on the table if it isn't the right fit for you — Veozah vs. HRT walks through how it stacks up against estrogen-based treatment for hot flashes specifically.